5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy by Cappuccini, F, Pollock, E, Stribbling, S, Hill, A, Redchenko, I

VANCE: First-in-human phase I study of a novel ChAdOx1-MVA 5T4 vaccine in low and intermediate risk prostate cancer by Redchenko, I, Cappuccini, F, Pollock, E, Bryant, R, Carter, L, Verrill, C, Hollidge, J, Goodwin, L, Harrop, R, Romero, P, Vigano, S, Evans, T, Catto, J, Hamdy, F, Hill, A

Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy by McAuliffe, J, Chan, HF, Noblecourt, L, Ramirez-Valdez, RA, Pereira-Almeida, V, Zhou, Y, Pollock, E, Cappuccini, F, Redchenko, I, Hill, AV, Leung, CSK, Van den Eynde, BJ

Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: A phase I clinical trial by Cappuccini, F, Bryant, R, Pollock, E, Carter, L, Verrill, C, Hollidge, J, Poulton, I, Baker, M, Mitton, C, Baines, A, Meier, A, Schmidt, G, Harrop, R, Protheroe, A, MacPherson, R, Kennish, S, Morgan, S, Vigano, S, Romero, PJ, Evans, T, Catto, J, Freddie Hamdy, Hill, AVS, Redchenko, I

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial... by Li, G, Cappuccini, F, Marchevsky, NG, Aley, PK, Aley, R, Anslow, R, Bibi, S, Cathie, K, Clutterbuck, E, Faust, SN, Feng, S, Heath, PT, Kerridge, S, Lelliott, A, Mujadidi, Y, Ng, KF, Rhead, S, Roberts, H, Robinson, H, Roderick, MR, Singh, N, Smith, D, Snape, MD, Song, R, Tang, K, Yao, A, Liu, X, Lambe, T, Pollard, AJ

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) by Flaxman, A, Marchevsky, NG, Jenkin, D, Aboagye, J, Aley, PK, Angus, B, Belij-Rammerstorfer, S, Bibi, S, Bittaye, M, Cappuccini, F, Cicconi, P, Clutterbuck, EA, Davies, S, Dejnirattisai, W, Dold, C, Ewer, KJ, Folegatti, PM, Fowler, J, Hill, AVS, Kerridge, S, Minassian, AM, Mongkolsapaya, J, Mujadidi, YF, Plested, E, Ramasamy, MN, Robinson, H, Sanders, H, Sheehan, E, Smith, H, Snape, MD, Song, R, Woods, D, Screaton, G, Gilbert, SC, Voysey, M, Pollard, AJ, Lambe, T

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials by Voysey, M, Flaxman, A, Aboagye, J, Aley, PK, Belij-Rammerstorfer, S, Bibi, S, Bittaye, M, Cappuccini, F, Charlton, S, Clutterbuck, EA, Davies, S, Dold, C, Edwards, NJ, Ewer, K, Faust, SN, Folegatti, PM, Fowler, J, Gilbride, C, Gilbert, SC, Godfrey, L, Hallis, B, Humphries, HE, Jenkin, D, Kerridge, S, Mujadidi, YF, Plested, E, Ramasamy, MN, Robinson, H, Sanders, H, Snape, MD, Song, R, Thomas, KM, Ulaszewska, M, Woods, D, Wright, D, Pollard, AJ, Lambe, T

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm sub-study of a phase 2/3 clinical trial by Frater, J, Ewer, K, Ogbe, A, Pace, M, Adele, S, Adland, E, Aley, P, Ali, M, Ansari, M, Bittaye, M, Brown, A, Brown, H, Cappuccini, F, Dejnirattisai, W, Dold, C, Moreira Folegatti, P, Fowler, J, Jenkin, D, Makinson, R, Marchevsky, N, Mujadidi, Y, Parolini, L, Plested, E, Ramasamy, M, Rhead, S, Robinson, H, Robinson, N, Rongkard, P, Tipoe, T, Zacharopoulou, P, Barnes, E, Goulder, P, Klenerman, P, Screaton, G, Hill, A, Gilbert, S, Pollard, AJ, Lambe, T

Booster vaccination against SARS-CoV-2 induces potent immune responses in people with human immunodeficiency virus by Fidler, S, Fox, J, Tipoe, T, Longet, S, Tipton, T, Abeywickrema, M, Adele, S, Alagaratnam, J, Ali, M, Aley, PK, Aslam, S, Balasubramanian, A, Bara, A, Bawa, T, Brown, A, Brown, H, Cappuccini, F, Davies, S, Fowler, J, Godfrey, L, Goodman, AL, Hilario, K, Hackstein, C-P, Mathew, M, Mujadidi, YF, Packham, A, Petersen, C, Plested, E, Pollock, KM, Ramasamy, MN, Robinson, H, Robinson, N, Rongkard, P, Sanders, H, Serafimova, T, Spence, N, Waters, A, Woods, D, Zacharopoulou, P, Barnes, E, Dunachie, S, Goulder, P, Klenerman, P, Winston, A, Hill, AVS, Gilbert, SC, Carroll, M, Pollard, AJ, Lambe, T, Ogbe, A, Frater, J

Durability of ChAdOx1 nCov-19 vaccination in people living with HIV by Ogbe, A, Pace, M, Bittaye, M, Tipoe, T, Adele, S, Alagaratnam, J, Aley, PK, Ansari, MA, Bara, A, Broadhead, S, Brown, A, Brown, H, Cappuccini, F, Cinardo, P, Dejnirattisai, W, Ewer, K, Fok, H, Folegatti, PM, Fowler, J, Godfrey, L, Goodman, AL, Jackson, B, Jenkin, D, Jones, M, Longet, S, Makinson, RA, Marchevsky, NG, Mathew, M, Mazzella, A, Mujadidi, YF, Parolini, L, Petersen, C, Plested, E, Pollock, K, Rajeswaran, T, Ramasamy, MN, Rhead, S, Robinson, H, Robinson, N, Sanders, H, Serrano Fandos, S, Tipton, T, Waters, A, Zacharopoulou, P, Barnes, E, Dunachie, S, Goulder, P, Klenerman, P, Screaton, GR, Winston, A, Gilbert, SC, Pollard, AJ, Lambe, T, Frater, J